The recent availability of antibodies that are specific for the mutations most clearly associated with response to EGFR TKIs, L858R and E746_A750del, create the opportunity to exploit an alternative method to evaluate NSCLC for EGFR mutations to aid decisions with regard to EGFR TKI therapy[11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.